Published in Biotech Business Week, September 27th, 2004
"We are excited about the submission of this NDA for Aczone," said David R. Bethune, Atrix's chairman and chief executive officer.
"We are proud of the extraordinary hard work, commitment, and dedication of the Aczone development team, made up of representatives from both Atrix and Fujisawa. The submission of this NDA illustrates...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.